NCT02650973View on ClinicalTrials.gov

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Healthy
Interventions
DRUG

CHS-1701

DRUG

Pegfilgrastim

Trial Locations (4)

45227

Medpace CPU, Cincinnati

53095

Spaulding, West Bend

90630

WCCT, Cypress

Unknown

ICON, San Antonio

Sponsors
All Listed Sponsors
lead

Coherus Oncology, Inc.

INDUSTRY

NCT02650973 - Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta | Biotech Hunter | Biotech Hunter